Ben Halladay News Today

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript February 27, 2024 Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.5, expectations were $-0.53. Esperion Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and […]

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2023 Earnings Call Transcript November 7, 2023 Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.37, expectations were $-0.42. Operator: Ladies and gentlemen, thank you for standing by and welcome to Esperion Therapeutics Third Quarter 2023 financial results call. At this time, all participants are in a lisen-only mode. […]

To commemorate Bourbon month, we recently sat down with noted whiskey expert Fred Minnick to talk about the state of bourbon in America

ANN ARBOR, Mich., July 24, 2023 -- Esperion today announced its participation in the BTIG Virtual Biotechnology Conference 2023. Ben Halladay, Chief Financial Officer, will participate in a...

ANN ARBOR, Mich., Nov. 16, 2022 -- Esperion today announced that Ben Halladay, MBA, has been promoted to the role of Chief Financial Officer from his prior position of Senior Director, Financial... | November 16, 2022

Ann Arbor-based drug company Esperion Therapeutics Inc. has a new top financial executive. Esperion (NASDAQ: ESPR) promoted Ben Halladay to CFO, it said in a news release late Wednesday. Halladay, 37, who joined Esperion in 2020 and was most recently a senior director of financial planning and…

ANN ARBOR, Mich., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Ben Halladay, MBA, has been promoted to the role of...

GuruFocus Article or News written by Value_Insider and the topic is about:

ESPR earnings call for the period ending June 30, 2022.